Nexalin Technology To Launch Clinical Trial Of Gen-3 Halo Headset For At-Home mTBI Treatment In Partnership With UC San Diego And San Diego VA; Study Builds On Results From Previous Trial And Aims To Expand Access To Care For Veterans
Portfolio Pulse from Benzinga Newsdesk
Nexalin Technology is set to launch a clinical trial for its Gen-3 Halo headset, aimed at treating mild traumatic brain injury (mTBI) at home. The trial, in partnership with UC San Diego and the San Diego VA, seeks to expand care access for veterans, building on previous trial results.
October 22, 2024 | 6:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nexalin Technology is launching a clinical trial for its Gen-3 Halo headset, in collaboration with UC San Diego and San Diego VA, to treat mTBI at home. This could enhance the company's product offerings and market reach, especially in veteran healthcare.
The partnership with reputable institutions like UC San Diego and San Diego VA adds credibility to Nexalin's Gen-3 Halo headset. The focus on veteran healthcare could open new market opportunities and improve the company's reputation, potentially boosting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90